Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$34.20M$34.20Mderived+5,261.1% vs Q4 2024 Net Income$20.13M$20.13MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$12,508,000N/M Operating Cash Flowderived-$11,250,000N/M Free Cash Flowderived-$11,269,000N/M Margins · derivedOperating margin36.6%+3930.9 pt vs Q4 2024
Net margin58.9%+2840.2 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end